Symbols / ONCY Stock $1.12 +0.90% Oncolytics Biotech Inc.
ONCY (Stock) Chart
About
No company description available for this symbol.
Stock Fundamentals
Scroll to Statements| Market Cap | 133.55M | Enterprise Value | — | Income | — | Sales | — | Book/sh | — | Cash/sh | — |
| Dividend Yield | — | Payout | — | Employees | — | IPO | — | P/E | — | Forward P/E | — |
| PEG | — | P/S | — | P/B | — | P/C | — | EV/EBITDA | — | EV/Sales | — |
| Quick Ratio | — | Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | — | EPS next Y | — |
| EPS Growth | — | Revenue Growth | — | Earnings | — | ROA | — | ROE | — | ROIC | — |
| Gross Margin | — | Oper. Margin | — | Profit Margin | — | Shs Outstand | — | Shs Float | — | Short Float | — |
| Short Ratio | — | Short Interest | — | 52W High | — | 52W Low | — | Beta | — | Avg Volume | — |
| Volume | — | Target Price | — | Recom | — | Prev Close | $1.11 | Price | $1.12 | Change | 0.90% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
—
Low
—
High
—
Mean
—
- ONCY (Oncolytics Biotech Inc. Common Shares) posts wider Q3 2025 loss than consensus estimates, shares rise 5.66 percent. - Social Investment Platform - Xã Thanh Hà hu, 23 Apr 2026 10
- Rare anal cancer with few options drives Oncolytics' FDA trial push - Stock Titan Mon, 06 Apr 2026 07
- ONCY Should I Buy - Intellectia AI Fri, 17 Apr 2026 07
- $ONCY stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 10 Apr 2026 19
- Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Wed, 03 Dec 2025 08
- Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat Mon, 06 Apr 2026 07
- Is Oncolytics Biotech (ONCY) Price Reset Creating A Long Term Opportunity? - simplywall.st Fri, 10 Apr 2026 07
- ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits Wed, 04 Feb 2026 17
- Oncolytics shifts to Nevada as San Diego becomes new headquarters - Stock Titan Wed, 01 Apr 2026 07
- Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For Pelareorep - Yahoo Finance Mon, 16 Feb 2026 08
- If You Invested $1,000 in Oncolytics Biotech Inc (ONCY) - Stock Titan Sun, 22 Mar 2026 07
- Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances - Yahoo Finance Mon, 12 Jan 2026 08
- Insider Purchase: Chief Executive Officer of $ONCY Buys 29,500 Shares | ONCY Stock News - Quiver Quantitative Fri, 13 Feb 2026 08
- Oncolytics Biotech (NASDAQ: ONCY) sets up $75M ATM facility - Stock Titan Mon, 06 Apr 2026 07
- Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal Cancer - Yahoo Finance Sun, 15 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
28.73
+12.46%
|
25.54
+0.28%
|
25.47
+28.40%
|
19.84
|
| Research And Development |
|
13.31
-13.79%
|
15.44
+15.69%
|
13.35
+17.40%
|
11.37
|
| Selling General And Administration |
|
15.41
+52.60%
|
10.10
-14.55%
|
11.82
+44.51%
|
8.18
|
| General And Administrative Expense |
|
15.41
+52.60%
|
10.10
-14.55%
|
11.82
+44.51%
|
8.18
|
| Salaries And Wages |
|
3.86
+13.33%
|
3.41
+14.60%
|
2.97
+4.07%
|
2.86
|
| Other Gand A |
|
11.55
+72.59%
|
6.69
-24.35%
|
8.85
+66.21%
|
5.32
|
| Other Operating Expenses |
|
—
|
—
|
—
|
—
|
| Total Expenses |
|
28.73
+12.46%
|
25.54
+0.28%
|
25.47
+28.40%
|
19.84
|
| Operating Income |
|
-28.73
-12.46%
|
-25.54
-0.28%
|
-25.47
-28.40%
|
-19.84
|
| Total Operating Income As Reported |
|
-28.73
-12.46%
|
-25.54
|
—
|
—
|
| EBITDA |
|
-28.66
-12.57%
|
-25.45
-1.14%
|
-25.17
-28.74%
|
-19.55
|
| Normalized EBITDA |
|
-28.70
-5.05%
|
-27.32
+5.11%
|
-28.79
-38.69%
|
-20.76
|
| Reconciled Depreciation |
|
0.07
-19.54%
|
0.09
-71.36%
|
0.30
+5.18%
|
0.29
|
| EBIT |
|
-28.73
-12.46%
|
-25.54
-0.28%
|
-25.47
-28.40%
|
-19.84
|
| Total Unusual Items |
|
0.05
-97.48%
|
1.87
-48.48%
|
3.63
+199.15%
|
1.21
|
| Total Unusual Items Excluding Goodwill |
|
0.05
-97.48%
|
1.87
-48.48%
|
3.63
+199.15%
|
1.21
|
| Net Income |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Pretax Income |
|
-28.68
-26.35%
|
-22.70
-8.89%
|
-20.85
-14.31%
|
-18.24
|
| Net Non Operating Interest Income Expense |
|
0.39
-60.41%
|
0.97
-2.46%
|
1.00
+156.93%
|
0.39
|
| Net Interest Income |
|
0.39
-60.41%
|
0.97
-2.46%
|
1.00
+156.93%
|
0.39
|
| Interest Income Non Operating |
|
0.39
-60.41%
|
0.97
-2.46%
|
1.00
+156.93%
|
0.39
|
| Interest Income |
|
0.39
-60.41%
|
0.97
-2.46%
|
1.00
+156.93%
|
0.39
|
| Other Income Expense |
|
-0.34
-118.25%
|
1.87
-48.48%
|
3.63
+199.15%
|
1.21
|
| Other Non Operating Income Expenses |
|
-0.39
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
0.05
-97.48%
|
1.87
-48.48%
|
3.63
+199.15%
|
1.21
|
| Tax Provision |
|
0.08
-16.84%
|
0.10
+29.92%
|
0.07
+18.14%
|
0.06
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.01
-97.48%
|
0.39
-48.48%
|
0.76
+199.15%
|
0.25
|
| Net Income Including Noncontrolling Interests |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Net Income From Continuing Operation Net Minority Interest |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Net Income From Continuing And Discontinued Operation |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Net Income Continuous Operations |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Normalized Income |
|
-28.80
-18.65%
|
-24.27
-2.04%
|
-23.78
-23.51%
|
-19.26
|
| Net Income Common Stockholders |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Diluted EPS |
|
—
|
-0.29
+7.57%
|
-0.31
+2.45%
|
-0.32
|
| Basic EPS |
|
—
|
-0.29
+7.57%
|
-0.31
+2.45%
|
-0.32
|
| Basic Average Shares |
|
—
|
76.48
+13.10%
|
67.62
+16.53%
|
58.03
|
| Diluted Average Shares |
|
—
|
76.48
+13.10%
|
67.62
+16.53%
|
58.03
|
| Diluted NI Availto Com Stockholders |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
0.30
-2.75%
|
0.30
+5.18%
|
0.29
|
| Depreciation And Amortization In Income Statement |
|
—
|
0.30
-2.75%
|
0.30
+5.18%
|
0.29
|
| Depreciation Income Statement |
|
—
|
0.30
-2.75%
|
0.30
+5.18%
|
0.29
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
29.26
|
| Current Assets |
|
28.78
|
| Cash Cash Equivalents And Short Term Investments |
|
26.32
|
| Cash And Cash Equivalents |
|
26.32
|
| Other Short Term Investments |
|
0.00
|
| Receivables |
|
0.01
|
| Other Receivables |
|
0.01
|
| Prepaid Assets |
|
2.45
|
| Hedging Assets Current |
|
0.00
|
| Total Non Current Assets |
|
0.49
|
| Net PPE |
|
0.49
|
| Gross PPE |
|
1.01
|
| Accumulated Depreciation |
|
-0.52
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.52
|
| Other Properties |
|
0.05
|
| Leases |
|
0.45
|
| Non Current Prepaid Assets |
|
0.00
|
| Total Liabilities Net Minority Interest |
|
8.49
|
| Current Liabilities |
|
3.19
|
| Payables And Accrued Expenses |
|
2.69
|
| Payables |
|
0.82
|
| Accounts Payable |
|
0.82
|
| Current Accrued Expenses |
|
1.88
|
| Current Debt And Capital Lease Obligation |
|
0.10
|
| Current Capital Lease Obligation |
|
0.10
|
| Other Current Liabilities |
|
0.40
|
| Total Non Current Liabilities Net Minority Interest |
|
5.29
|
| Long Term Debt And Capital Lease Obligation |
|
0.22
|
| Long Term Capital Lease Obligation |
|
0.22
|
| Non Current Deferred Liabilities |
|
5.07
|
| Non Current Deferred Revenue |
|
5.07
|
| Stockholders Equity |
|
20.78
|
| Common Stock Equity |
|
20.78
|
| Capital Stock |
|
324.82
|
| Common Stock |
|
324.82
|
| Share Issued |
|
74.42
|
| Ordinary Shares Number |
|
74.42
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
31.75
|
| Retained Earnings |
|
-336.20
|
| Gains Losses Not Affecting Retained Earnings |
|
0.41
|
| Other Equity Adjustments |
|
0.41
|
| Total Equity Gross Minority Interest |
|
20.78
|
| Total Capitalization |
|
20.78
|
| Working Capital |
|
25.58
|
| Invested Capital |
|
20.78
|
| Total Debt |
|
0.32
|
| Capital Lease Obligations |
|
0.32
|
| Net Tangible Assets |
|
20.78
|
| Tangible Book Value |
|
20.78
|
| Other Equity Interest |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-20.11
-1.15%
|
-19.88
+7.28%
|
-21.44
-24.62%
|
-17.21
|
| Cash Flow From Continuing Operating Activities |
|
-20.11
-1.15%
|
-19.88
+7.28%
|
-21.44
-24.62%
|
-17.21
|
| Net Income From Continuing Operations |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Depreciation Amortization Depletion |
|
0.07
-19.54%
|
0.09
-71.36%
|
0.30
+5.18%
|
0.29
|
| Depreciation |
|
0.07
-19.54%
|
0.09
-71.36%
|
0.30
+5.18%
|
0.29
|
| Depreciation And Amortization |
|
0.07
-19.54%
|
0.09
-71.36%
|
0.30
+5.18%
|
0.29
|
| Other Non Cash Items |
|
4.20
+1312.46%
|
0.30
+454.93%
|
0.05
+195.58%
|
-0.06
|
| Stock Based Compensation |
|
3.10
+56.61%
|
1.98
+27.14%
|
1.56
-11.03%
|
1.75
|
| Operating Gains Losses |
|
0.10
+104.95%
|
-1.98
+47.55%
|
-3.77
-218.90%
|
-1.18
|
| Gain Loss On Investment Securities |
|
0.23
+120.10%
|
-1.17
+70.66%
|
-3.98
-27134.53%
|
0.01
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.14
+83.07%
|
-0.81
-480.57%
|
0.21
+117.75%
|
-1.20
|
| Change In Working Capital |
|
1.18
-53.23%
|
2.52
+89.63%
|
1.33
+361.82%
|
0.29
|
| Change In Receivables |
|
2.94
+8485.71%
|
-0.04
-109.18%
|
0.38
+50.05%
|
0.25
|
| Changes In Account Receivables |
|
2.93
+73200.00%
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
0.58
-41.47%
|
0.99
+69.20%
|
0.59
+163.75%
|
-0.92
|
| Change In Payables And Accrued Expense |
|
-0.36
-140.72%
|
0.88
+1603.48%
|
-0.06
-104.80%
|
1.22
|
| Change In Accrued Expense |
|
-0.36
-140.72%
|
0.88
|
—
|
—
|
| Change In Other Working Capital |
|
-1.68
-279.70%
|
0.94
+444.60%
|
0.17
+1472.11%
|
-0.01
|
| Change In Other Current Liabilities |
|
-0.29
-15.81%
|
-0.25
-201.09%
|
0.25
+196.49%
|
-0.26
|
| Investing Cash Flow |
|
-0.01
+96.55%
|
-0.17
-101.14%
|
15.24
+201.40%
|
-15.03
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
+96.55%
|
-0.17
-101.14%
|
15.24
+201.40%
|
-15.03
|
| Net PPE Purchase And Sale |
|
-0.01
+96.55%
|
-0.17
-2785.35%
|
-0.01
+85.12%
|
-0.04
|
| Purchase Of PPE |
|
-0.01
+96.55%
|
-0.17
-2785.35%
|
-0.01
+85.12%
|
-0.04
|
| Capital Expenditure |
|
-0.01
+96.55%
|
-0.17
-2785.35%
|
-0.01
+85.12%
|
-0.04
|
| Net Investment Purchase And Sale |
|
—
|
0.00
-100.00%
|
15.25
+201.71%
|
-14.99
|
| Purchase Of Investment |
|
—
|
0.00
|
0.00
+100.00%
|
-14.99
|
| Sale Of Investment |
|
—
|
0.00
-100.00%
|
15.25
|
0.00
|
| Financing Cash Flow |
|
14.12
+180.83%
|
5.03
-79.15%
|
24.12
+168.19%
|
8.99
|
| Cash Flow From Continuing Financing Activities |
|
14.12
+180.83%
|
5.03
-79.15%
|
24.12
+168.19%
|
8.99
|
| Net Issuance Payments Of Debt |
|
—
|
-0.24
+20.97%
|
-0.31
-9.29%
|
-0.28
|
| Repayment Of Debt |
|
—
|
-0.24
+20.97%
|
-0.31
-9.29%
|
-0.28
|
| Long Term Debt Payments |
|
—
|
-0.24
+20.97%
|
-0.31
-9.29%
|
-0.28
|
| Net Long Term Debt Issuance |
|
—
|
-0.24
+20.97%
|
-0.31
-9.29%
|
-0.28
|
| Net Common Stock Issuance |
|
11.77
+136.24%
|
4.98
-79.10%
|
23.84
+157.27%
|
9.26
|
| Proceeds From Stock Option Exercised |
|
2.38
+4963.83%
|
0.05
-92.02%
|
0.59
+6558.46%
|
0.01
|
| Net Other Financing Charges |
|
-0.03
|
—
|
—
|
—
|
| Changes In Cash |
|
-6.00
+60.09%
|
-15.03
-183.88%
|
17.92
+177.06%
|
-23.25
|
| Effect Of Exchange Rate Changes |
|
0.12
+141.87%
|
-0.29
+26.55%
|
-0.39
-127.29%
|
1.44
|
| Beginning Cash Position |
|
11.08
-58.03%
|
26.40
+200.17%
|
8.79
-71.07%
|
30.40
|
| End Cash Position |
|
5.20
-53.05%
|
11.08
-57.90%
|
26.32
+206.17%
|
8.60
|
| Free Cash Flow |
|
-20.12
-0.30%
|
-20.06
+6.50%
|
-21.45
-24.36%
|
-17.25
|
| Income Tax Paid Supplemental Data |
|
—
|
0.13
+41.73%
|
0.09
+166.89%
|
0.03
|
| Common Stock Issuance |
|
11.77
+136.24%
|
4.98
-79.10%
|
23.84
+157.27%
|
9.26
|
| Issuance Of Capital Stock |
|
11.77
+136.24%
|
4.98
-79.10%
|
23.84
+157.27%
|
9.26
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-06 View
- 8-K2026-04-06 View
- 8-K2026-04-01 View
- 10-K2026-03-30 View
- 8-K2026-03-20 View
- 8-K2026-03-19 View
- 42026-03-13 View
- 42026-03-13 View
- 8-K2026-03-02 View
- 8-K2026-02-24 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 8-K2026-02-04 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|